Long-term Complications:Ewing Sarcoma Treatment

Original Article

Complications in long-term survivors of Ewing sarcoma Bruno Fuchs, M.D. 1 *, Richard G. Valenzuela, M.D. 1, Carrie Inwards, M.D. 2, Franklin H. Sim, M.D. 1, Michael G. Rock, M.D. 1

1Department of Orthopedics, Mayo Clinic, Rochester, Minnesota 2Department of Surgical Pathology, Mayo Clinic, Rochester, Minnesota

email: Bruno Fuchs (fuchs.bruno@mayo.edu)

*Correspondence to Bruno Fuchs, Division of Orthopedic Oncology, Department of Orthopaedic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905

Fax: (507) 284-5075

Abstract

BACKGROUND

Multimodality treatment has dramatically improved the outcome of patients with Ewing sarcoma. However, there appears to be little information concerning treatment-related complications in patients who are long-term survivors.

METHODS

Forty-one patients with Ewing sarcoma who were treated between 1960-1980 and who survived the disease by at least 20 years were included in the current study. In a retrospective analysis, all complications related to the multimodality treatment of Ewing sarcoma were assessed.

RESULTS

The patient group was comprised of 17 men and 24 women, with a mean age at the time of presentation of 16.8 years (range, 5-51 years). Approximately 20% of the lesions were located in the pelvis. All but 9 patients (78%) received chemotherapy as part of their treatment.

The overall follow-up period averaged 25 years (range, 20-36 years). All except 1 patient were alive at the time of final follow-up, with the latter patient dying of radiation-induced secondary malignancy after 33 years.

Only 17 patients (41%) were found to be free of any complication. These included metastases, local recurrence, secondary malignancies, pathologic fractures, and radiation-associated and chemotherapy-associated morbidities.

CONCLUSIONS

Although the patients in the current study were treated successfully in terms of surviving an aggressive tumor, the high complication rate in this group of long-term survivors is noteworthy and indicates that long-term follow-up should be mandatory.

Cancer 2003;98:2687-92.

Remember we are NOT Doctors and have NO medical training.

This site is like an Encylopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.